NK

Nishi Kumari

Director Director DIN 07710960
DIN 07710960 First appointment Feb 2017 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Feb 2017
Shareholding value β€’β€’β€’β€’ Premium profile

About Nishi Kumari

Data last updated:

Nishi Kumari was a Director at Kelly Pharmaceuticals Private Limited (2018–2022) and Director at Spiros Pharmaceutical Private Limited (from 2017). The companies operate in Pharma.

DIN 07710960
Primary Designation Director
Industry Pharma
First Appointment 13 Feb 2017
Oldest Company Age 9 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director25 Apr 20182018₹1.56 Cr (FY 2024)Active
Director13 Feb 20172017Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Spiros Pharmaceutical Private Limited
Kelly Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Nishi Kumari

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nishi Kumari

Nishi Kumari was first appointed on 13 Feb 2017 as Director at Spiros Pharmaceutical Private Limited. The most recent appointment on record is 25 Apr 2018 at Kelly Pharmaceuticals Private Limited.

Nishi Kumari held 2 earlier board appointments: Kelly Pharmaceuticals Private Limited (Director, 25 Apr 2018 to 03 Feb 2022); Spiros Pharmaceutical Private Limited (Director, from 13 Feb 2017).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available